System-c bioprocess, Aurogene and Labsoft have recently been appointed to respectively represent Phase Holographic Imaging (PHI) in France, Italy and Poland.
For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.
A major publicly traded life science tools company has entered a technology assessment agreement with Phase Holographic Imaging (PHI). The purpose of the agreement is to assess PHI’s Holo¬Monitor technology for cell biology applications, primarily within immuno-oncology.
In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments.
Scientists at the Holographic Imaging Cytometry Center of Excellence at University of California, San Francisco, study how normal skin cells transform into aggressive skin cancer. HoloMonitor M4 plays an important role in their research.
For the first time, sales during the past 12 months reached 5 MSEK. Since our previous report, much effort has gone into implementing the ambitious market expansion made possible by the capital acquisition this summer.
Baserat på PHI:s befintliga HoloMonitor-teknik, har institutionen för Immunteknologi vid Lunds Universitet och Phase Holographic Imaging (PHI) avtalat om att gemensamt utveckla nya metoder för 3‑dimensionell cellodling. Detta för att möta ett akut och snabbt växande behov av dessa metoder inom cancerforskningen.
Based on PHI’s current HoloMonitor technology, the Department of Immunotechnology at Lund University and Phase Holographic Imaging (PHI) recently agreed to jointly develop novel 3-dimensional cell culturing methods to meet the urgent need for such methods.
The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.